Ascendis åbner nyt selskab for at nå Kina

Sammen med kapitalfonden Vivo Capital har Ascendis Pharma stiftet et nyt selskab i Kina, som skal hjælpe virksomheden med at slå igennem på de kinesiske marked med Ascendis' tre hovedprodukter.

Photo: Andy Wong/AP

Med 40 mio. dollar (cirka 263 mio. kr.) i ryggen fra et investorsyndikat ledet af Vivo Capital har Ascendis Pharma smedet et nyt selskab i Kina, Visen Pharmaceuticals.

Det oplyser parterne i en pressemeddelelse.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from AMWatch

ATP's managed assets maintained growth in Q3

A positive result from investments and a negative hedging portfolio outcome are the main takeaways from ATP's Q3 report, which reports that total managed assets have increased, and the bonus rate has also swelled further.

Velliv divests coal and tar sands

Neither coal nor oil extracted from tar sands will be be found in Velliv's portfolio now that the company has decided to completely exclude companies associated with those activites.

Related articles

Trial banner

Latest news


Latest news from FinansWatch (dk)

Latest news from EnergyWatch

Latest news from ShippingWatch